Evidence map›Paper›PMID 42199862›Full record

ArticleFrontiers in pharmacology2026

Platelet-membrane-coated nanoparticles enable safe and targeted thrombolysis with preserved neurovascular integrity.

Ziying Feng, Ogunleye Femi Abiola, Guojun Huang, Tianfang Kang, Fan Xu, Ping Gong, Junlei Chang, Hong Pan, Yinzhong Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ziying Feng *State Key Laboratory of Biomedical Imaging Science and System, Guangdong-Hong Kong Joint Laboratory for Metabolic Medicine, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.
Ogunleye Femi Abiola *State Key Laboratory of Biomedical Imaging Science and System, Guangdong-Hong Kong Joint Laboratory for Metabolic Medicine, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.
Guojun Huang *University of Chinese Academy of Sciences, Beijing, China.
Tianfang KangUniversity of Chinese Academy of Sciences, Beijing, China.
Fan XuDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden.
Ping GongGuangdong Key Laboratory of Nanomedicine, CAS-HK Joint Lab of Biomaterials, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.
Junlei ChangState Key Laboratory of Biomedical Imaging Science and System, Guangdong-Hong Kong Joint Laboratory for Metabolic Medicine, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.
Hong PanUniversity of Chinese Academy of Sciences, Beijing, China.
Yinzhong MaState Key Laboratory of Biomedical Imaging Science and System, Guangdong-Hong Kong Joint Laboratory for Metabolic Medicine, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant tissue-type plasminogen activator (rtPA) is the only FDA-approved thrombolytic agent for acute ischemic stroke, yet its clinical utility is constrained by a narrow therapeutic time window, rapid clearance, and hemorrhagic transformation risk. Here, we developed a biomimetic nanothrombolytic comprising rtPA-conjugated, platelet-membrane-coated PLGA nanoparticles loaded with perfluorohexane (PNP-rtPA) to improve thrombus specificity and vascular safety. PNP-rtPA preserved rtPA enzymatic activity, achieved efficient fibrin clot lysis

Indexed as

biomimetic nanoparticlesischemic strokeplatelet membrane coatingrecombinant tissue-type plasminogen activator (rtPA)thrombolytic therapy

Identifiers

PMID42199862
PMCPMC13199308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.